<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Functional abdominal pain in children and adolescents: Management in primary care</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Functional abdominal pain in children and adolescents: Management in primary care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Functional abdominal pain in children and adolescents: Management in primary care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mariam R Chacko, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric H Chiou, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy B Middleman, MD, MPH, MS Ed</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanghamitra M Misra, MD, MEd</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Functional abdominal pain disorders (FAPDs), also called pain-predominant functional gastrointestinal disorders, are the most common cause of chronic abdominal pain in children and adolescents. FAPDs involve interplay among regulatory factors in the enteric and central nervous systems [<a href="#rid1">1</a>]. FAPDs may be associated with visceral hyperalgesia, reduced threshold for pain, abnormal pain referral after rectal distension, or impaired gastric relaxation response to meals [<a href="#rid2">2-6</a>]. In addition, persistent experiences of pain may have an adverse effect on mental health. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Pathogenesis'</a>.)</p><p>The management of children and adolescents with FAPDs is reviewed here. The evaluation of children and adolescents with chronic abdominal pain, treatment of migraine in children (including abdominal migraine), and FAP in adults are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6202.html" rel="external">"Types of migraine and related syndromes in children", section on 'Abdominal migraine'</a> and  <a class="medical medical_review" href="/z/d/html/6168.html" rel="external">"Acute treatment of migraine in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/19.html" rel="external">"Functional dyspepsia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults"</a>.)</p><p></p><p class="headingAnchor" id="H79257292"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Functional abdominal pain (FAP) may be diagnosed in children who have all of the following [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic (≥2 months) abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>No alarm findings  (<a class="graphic graphic_table graphicRef90721" href="/z/d/graphic/90721.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal physical examination</p><p class="bulletIndent1"><span class="glyph">●</span>Stool sample negative for occult blood</p><p></p><p>Several pain-predominant functional gastrointestinal disorders of childhood have recognizable patterns of symptoms and include functional dyspepsia, irritable bowel syndrome (IBS), abdominal migraine, and FAP-not otherwise specified (FAP-NOS)  (<a class="graphic graphic_table graphicRef71435" href="/z/d/graphic/71435.html" rel="external">table 2</a>) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Diagnosis of functional abdominal pain'</a>.)</p><p>Terms that have been used interchangeably with FAP-NOS (often referred to as FAP) include "nonorganic abdominal pain," "psychogenic abdominal pain," and "recurrent abdominal pain." Although the American Academy of Pediatrics and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition clinical report on chronic abdominal pain recommended not using the term "recurrent abdominal pain" as a synonym for functional, psychological, or stress-related abdominal pain, this use persists [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H308413537"><span class="h1">MANAGEMENT APPROACH</span><span class="headingEndMark"> — </span>The goal of management of functional abdominal pain disorders (FAPDs) in children and adolescents is return to normal function (ie, rehabilitation) rather than complete elimination of pain [<a href="#rid1">1,8,10-12</a>]. Most cases can be managed in the primary care setting [<a href="#rid13">13</a>]. Referral may be necessary for children and adolescents who do not improve with primary care interventions. (See <a class="local">'Indications for referral'</a> below.)</p><p>The management of FAPDs is challenging because the subtypes are heterogeneous and the pathophysiology is incompletely understood. Individuals with FAPDs may have similar symptoms (eg, abdominal pain, nausea, changes in bowel movements) but different underlying causes. Thus, management is individualized according to child and family behaviors, triggers, and symptoms [<a href="#rid14">14,15</a>].</p><p>"Response" to any intervention may reflect the natural history of improvement over time or placebo response as FAPDs resolve with time in the majority of children [<a href="#rid16">16-18</a>].</p><p>In a meta-analysis of 17 placebo-controlled randomized trials (pharmacologic or nonpharmacologic) in children age 4 to 18 years with an abdominal pain-related functional gastrointestinal disorder, the pooled placebo response rate for improvement (as defined by the study authors) was 41 percent (95% CI 34-49 percent) and the pooled placebo response rate for no pain was 17 percent (95% CI 8-32 percent) [<a href="#rid19">19</a>]. Although the study did not identify any factors that could be used in clinical practice to optimize the placebo response, the high placebo response rate can be a valuable tool to enhance any treatment strategy. (See <a class="local">'Prognosis'</a> below.)</p><p>The detailed recommendations in the sections below are generally consistent with those outlined in the 2005 American Academy of Pediatrics and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnaspghan.org%2Ffiles%2Fdocuments%2Fpdfs%2Fposition-papers%2FChronic+abdominal+pain+-+clinical+report.pdf&amp;token=mA4eNWBB%2BRfrUCM5At3iUn2712L1TsHRYFCBAptbiQs%2B%2Fhxy7PxdYWkFzo3fP1P8Tj%2F8dlXdKLvxTlAe4Lb8x2t3Tt5pgA7rNnqZ1Ci1JWos0Z8HZJp3jT%2FzJm%2BiPX3U&amp;TOPIC_ID=112" target="_blank">clinical report on chronic abdominal pain in children</a> [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H67027684"><span class="h1">GENERAL MANAGEMENT STRATEGIES</span><span class="headingEndMark"> — </span>The approach to functional abdominal pain disorders (FAPDs) in children and adolescents typically involves various combinations of: a therapeutic relationship, behavior modification, strategies to improve pain tolerance and coping, avoidance of triggers, and symptomatic management [<a href="#rid20">20,21</a>]. For patients whose pain remains unrelenting and continues to interfere with functioning, referral for noninvasive interventions such as hypnotherapy and auricular neuromodulation may be warranted. Although additional study is necessary, evidence from well-designed, single-center trials supports the efficacy of these interventions.</p><p class="headingAnchor" id="H3"><span class="h2">Therapeutic relationship</span><span class="headingEndMark"> — </span>A therapeutic clinician-patient/family relationship is an important component of the management of FAPDs. The patient and family must believe that their complaints and concerns are taken seriously [<a href="#rid21">21,22</a>]. Their concerns about specific organic diseases must be addressed (generally by reviewing the manifestations of that disease that are absent in the patient) before management of FAPDs can proceed [<a href="#rid12">12</a>]. The explanation of a biopsychosocial model of functional disease can be helpful  (<a class="graphic graphic_figure graphicRef90722" href="/z/d/graphic/90722.html" rel="external">figure 1</a>), as it frames the disease in terms of being a positive diagnosis rather than a diagnosis of exclusion (with the inherent expectation for extensive evaluation). The family's ability to accept such a biopsychosocial model of pain may be an important factor in the child's recovery [<a href="#rid23">23</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p>Some centers have developed a multidisciplinary model of care for patients with FAPDs, usually including a pediatric gastroenterologist, pain specialist, and psychologist. The multidisciplinary team reinforces the biopsychosocial aspects of FAPDs and demonstrates that the patient's and family's concerns are being taken seriously. In observational studies, multidisciplinary care has been associated with reduced pain, increased function, and decreased health care utilization in children with FAPDs [<a href="#rid24">24,25</a>].</p><p>The patient and family may be reassured by the clinician's acknowledging that the pain is real and has affected important activities in the patient's life. The patient and family should be assured that the clinician will initiate a treatment plan and continue to regularly follow up with the patient [<a href="#rid26">26</a>]. Periodic follow-up validates the clinician's continued support and interest in the patient and family. (See <a class="local">'Follow-up'</a> below.)</p><p>The therapeutic alliance may be strengthened by focusing on the shared goal of return to normal function for both the patient and family. The pain may be a focal point of the family's life, creating stress for other members. The pediatric care provider can address these effects by prescribing a return to structured activities of daily living, including school attendance (a rehabilitative approach). (See <a class="local">'Return to school'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Patient education</span><span class="headingEndMark"> — </span>FAPDs are best treated in the context of a biopsychosocial model of care  (<a class="graphic graphic_figure graphicRef90722" href="/z/d/graphic/90722.html" rel="external">figure 1</a>) [<a href="#rid8">8,27-32</a>]. In small observational study, caregiver acceptance of a biopsychosocial model of illness was associated with resolution of pain [<a href="#rid23">23</a>].</p><p>Before beginning therapy, the pediatric health care provider should clarify the expectations of the caregivers and patient. Some caregivers may simply want assurance that the pain is not caused by organic illness. Expectations must be realistic (eg, improved function or school attendance rather than complete resolution of pain) [<a href="#rid8">8</a>].</p><p>Education should include the following points:</p><p class="bulletIndent1"><span class="glyph">●</span>FAPDs are common, occurring in approximately 10 to 20 percent of children. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pain of FAPDs is real; it is thought to be caused by a heightened sensitivity to the normal function of the stomach and bowel. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Like other types of pain, pain in FAPDs can be triggered, exacerbated, or maintained by environmental (eg, gastrointestinal infection, medications) and psychosocial factors, including stress, anxiety, and social reinforcement (eg, attention, staying home from school) [<a href="#rid11">11,21,33,34</a>].</p><p></p><p class="bulletIndent1">Other examples of physiologic responses to stress or anxiety include headaches, churning of the stomach before a test, and nausea when given bad news.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pain of FAPDs is not life-threatening and does not require activity restriction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment focuses on rehabilitation: return to normal activity despite discomfort [<a href="#rid10">10,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of pain involves avoiding triggers and improving coping skills; the pain may persist, but the child's and family's quality of life can be improved [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Goals for management should be realistic (eg, maintenance of normal activities, increased tolerance of symptoms) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pain, regardless of the etiology, can be associated with depression or anxiety (both as a cause and an effect) [<a href="#rid35">35</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="headingAnchor" id="H255397623"><span class="h2">Return to school</span><span class="headingEndMark"> — </span>A plan for return to school is crucial. School absenteeism adds to family stress and can interfere with the patient's school performance and social functioning [<a href="#rid36">36</a>]. Homebound schooling is strongly discouraged unless the clinician and school counselor agree that it is necessary (eg, based on academic performance or needs).</p><p>In most cases, return to school should immediately follow the diagnosis of FAPD [<a href="#rid12">12</a>]. Caregivers who are concerned about their child's emotional reaction to returning to school may need help in formulating and implementing a plan for graded return to school. They can be encouraged to work with the school to develop a part-time schedule to facilitate the transition. The first day back should be sufficiently short to guarantee success and increase the child and family's confidence in the child's ability to attend school [<a href="#rid12">12</a>].</p><p>Return to school may be facilitated by [<a href="#rid12">12,36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Planning ahead for pain episodes at school (eg, being allowed to go to the nurse's office until pain subsides with the caveat that regular use of the nurse's office at school may reinforce symptoms).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing guidelines to help the caregiver decide when the child is too sick to go to school or sick enough to be allowed to come home (eg, fever, vomiting, diarrhea). Regularly sending the child home from school may reinforce symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing guidelines for activity restriction when the child remains home from school (eg, bedrest without television or other entertainment).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying and addressing school-related sources of stress (eg, bullying, social isolation, inappropriate classroom placement).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with FAPD and altered bowel patterns, sending a letter requesting that the child be allowed to use the bathroom whenever necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For families who have an adversarial relationship with the school related to frequent absence, sending a letter to document that the child has undergone an evaluation for gastrointestinal symptoms that have interfered with attendance.</p><p></p><p class="headingAnchor" id="H571383545"><span class="h2">Behavior modification</span><span class="headingEndMark"> — </span>Return to normal function is facilitated by reinforcement of nonpain (healthy or adaptive) behaviors and avoiding/stopping reinforcement of pain (sick, illness, or maladaptive) behaviors [<a href="#rid12">12,37</a>]. Suggestions for behavior modification techniques may be provided by the primary care provider and/or, as necessary, in a more formal psychotherapy program (eg, cognitive behavior therapy [CBT]).</p><p>Examples of reinforcement of well behaviors include [<a href="#rid12">12,34,38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Praising/rewarding the child for attending school or extracurricular activities (eg, using a sticker chart to earn rewards agreed upon in advance for progressively longer periods of consecutive attendance)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying and supporting the child's interests and skills outside of the sick role (eg, athletic or artistic abilities)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caregiver modeling of healthy responses to abdominal pain (eg, deep breathing) (see <a class="local">'Improved coping'</a> below)</p><p></p><p>In attempts to be supportive and nurturing, caregivers of children with FAPDs may inadvertently reinforce pain or illness behaviors [<a href="#rid21">21</a>]. Examples of reinforcement of pain behavior that should be avoided include [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Providing attention to the pain (eg, asking about symptoms); in a randomized trial, spontaneous complaints of pain during symptom provocation (water load) nearly doubled among children whose caregivers were assigned to provide attention (eg, "I can imagine it must feel really uncomfortable") compared with children whose caregivers were not provided with any specific instruction [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Scheduling a "symptom report" once per day may be helpful for caregivers and children who have difficulty with immediate and complete discontinuation of asking about or reporting symptoms [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allowing the pain to disrupt normal function and activity (eg, by allowing the child to stay home from school or leave school, excusing the child from completing their homework) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allowing the child who stays home from school to watch television or have access to other forms of entertainment.</p><p></p><p class="headingAnchor" id="H255397635"><span class="h2">Improved coping</span><span class="headingEndMark"> — </span>Coping is defined as voluntary efforts to regulate emotion, thought, behavior, physiology, and the environment in response to stressful events or circumstances [<a href="#rid41">41</a>]. We suggest incorporation of psychological treatments to improve coping in the management of children and adolescents with FAPDs.</p><p>Learning to cope with pain facilitates return to normal function. Randomized and observational studies provide relatively compelling but limited evidence that psychological interventions (eg, relaxation, distraction [including guided imagery/hypnotherapy], CBT, biofeedback) are associated with improved pain tolerance, reduced anxiety, increased nonpain behavior, and improved self-management [<a href="#rid42">42-44</a>].</p><p>Although few studies directly compare psychological interventions with "standard pediatric care" (which typically involves education and reassurance with or without dietary interventions or pharmacotherapy), psychological interventions appear to be more effective [<a href="#rid45">45-50</a>]. (See <a class="local">'Behavior modification'</a> above.)</p><p>Relaxation and distraction techniques can be taught by trained primary care clinicians; CBT and biofeedback typically require referral to mental health professionals with specialized training [<a href="#rid51">51</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relaxation techniques</strong> – Older children and adolescents can be taught brief muscle relaxation techniques such as deep breathing exercises to be performed at least twice a day  (<a class="graphic graphic_table graphicRef90731" href="/z/d/graphic/90731.html" rel="external">table 3</a>) [<a href="#rid10">10</a>]. A family member can act as "coach" if necessary. The goal is to help the child or adolescent relax when in pain.</p><p></p><p class="bulletIndent1">Progressive muscle relaxation is another relaxation technique that involves systematic tensing and relaxing of each muscle group, focusing attention on the feeling after the muscles are relaxed  (<a class="graphic graphic_table graphicRef90731" href="/z/d/graphic/90731.html" rel="external">table 3</a>) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">In observational studies and meta-analyses, relaxation therapy helped to reduce pain and improve function in children with FAPDs [<a href="#rid38">38,52-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distraction</strong> – Distraction shifts attention away from pain [<a href="#rid55">55</a>]. Distraction techniques include conversation, games, television, and guided imagery. In a randomized trial, spontaneous complaints of pain during symptom provocation (water load) were reduced by one-half among children whose caregivers were assigned to provide distraction (eg, "What would you like to do this evening?") attention compared with children whose caregivers were not provided with any specific instruction [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guided imagery/hypnotherapy</strong> – Guided imagery (also called hypnotherapy or self-hypnosis) is a distraction technique through which the child engages in imagery and relaxation, which distracts attention from painful stimuli [<a href="#rid46">46,56</a>]. Guided imagery may incorporate imagined pictures, sounds, or sensations to produce increased receptiveness to gut-specific suggestions and ideas, also known as "gut-directed" hypnotherapy  (<a class="graphic graphic_table graphicRef90731" href="/z/d/graphic/90731.html" rel="external">table 3</a>). Guided imagery/hypnotherapy may be self-directed or performed by a qualified therapist [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">In a 2017 meta-analysis of four small randomized trials including 146 children with recurrent abdominal pain [<a href="#rid45">45,46,58,59</a>], guided imagery/hypnotherapy was more successful (defined as being pain free or an improvement in pain, according to the individual study) than control medical therapy (absolute rate of improvement 53 versus 14 percent; odds ratio 6.8, 95% CI 2.4-19) [<a href="#rid43">43</a>]. Guided imagery/hypnotherapy also was effective in reducing pain intensity and frequency and reducing missed activities. In long-term follow-up from one trial [<a href="#rid45">45</a>], the beneficial effects of guided imagery/hypnotherapy were sustained for five years [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">A subsequent trial, in which 260 children with FAPDs (age range 8 to 18 years) were randomly assigned to three months of self-administered home-based gut-directed hypnotherapy using a compact disc or individual gut-directed hypnotherapy with a qualified therapist, confirmed the effectiveness of both hypnotherapy approaches [<a href="#rid57">57</a>]. Although self-directed hypnotherapy was less effective than therapist-directed hypnotherapy at three months, outcomes at one and six years were similar [<a href="#rid57">57,61</a>]. Self-directed hypnotherapy may be an appealing option for older children and adolescents accepting of the self-administered approach, particularly if trained therapists are not available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CBT</strong> – CBT is a psychotherapy approach that identifies links between behavior, thoughts, and feelings to effect therapeutic change [<a href="#rid29">29,62</a>]. An individual CBT program may include various combinations of education, relaxation, stress management, and behavior modification techniques [<a href="#rid29">29,63</a>]. Provision of CBT requires specialized training and is usually provided by a psychologist. (See  <a class="medical medical_review" href="/z/d/html/14612.html" rel="external">"Overview of psychotherapies", section on 'Cognitive and behavioral therapies'</a> and <a class="local">'Behavior modification'</a> above and <a class="local">'Indications for referral'</a> below.)</p><p></p><p class="bulletIndent1">Thinking positively and avoidance of counterproductive coping strategies appear to be important targets for CBT. In an observational study of 117 children with FAP, children's and caregivers' confidence in the child's potential to cope with abdominal pain (ie, thinking positively) was associated with improved functioning and decreased abdominal pain, whereas passive coping strategies (eg, self-isolation, catastrophizing, and disengagement) were associated with more symptoms of anxiety and depression [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">A 2022 systematic review of psychosocial interventions for children with FAPDs found moderate-certainty evidence of treatment success with CBT compared with no intervention (38 versus 15 percent; risk ratio 2.37, 95% CI 1.30-4.34; six trials, 324 children); treatment success was defined dichotomously, but different criteria were used in different trials [<a href="#rid44">44</a>]. The systematic review also found moderate-certainty evidence of decreased pain frequency and pain intensity with CBT compared with no intervention. There was low certainty in evidence for studies comparing CBT with other modalities (eg, educational support, hypnotherapy, guided imagery) due to imprecision and risk of bias from lack of blinding. In one of the included trials, children with FAPDs assigned to 10 weeks of internet-delivered CBT had greater improvements in symptom severity and quality of life than those assigned to usual treatment (eg, treatment within the health care and school systems, including medications); benefits persisted through 36 weeks of follow-up [<a href="#rid62">62</a>]. Internet-delivered CBT also produced substantial cost savings per patient and has the potential to increase the availability of cost-effective treatment for FAPDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biofeedback – Biofeedback is a technique that provides a visual or auditory display of the physiologic responses to pain/anxiety (eg, heart rate, skin temperature) so that the effects of relaxation techniques can be externally validated [<a href="#rid30">30,51,55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Yoga – Yoga is commonly used as a relaxation technique to lessen stress and anxiety [<a href="#rid65">65,66</a>]. A 2022 systematic review of three randomized trials comparing yoga or yoga therapy (a mixture of yoga poses, meditation, and relaxation exercises) with no intervention in a total of 127 children with FAPDs did not detect a benefit with yoga on pain, quality of life, or daily activities [<a href="#rid44">44,65,67,68</a>]. However, in a subsequently published randomized trial, a combination yoga/dance intervention twice weekly for eight months was superior to standard care in reducing maximum pain in 121 females age 9 to 13 years with FAPDs [<a href="#rid69">69</a>]. Given the limited evidence, we do not suggest yoga as a routine intervention in the management of children and adolescents with FAPDs.</p><p></p><p class="headingAnchor" id="H67027703"><span class="h1">MANAGEMENT OF TRIGGERS</span><span class="headingEndMark"> — </span>Avoidance of triggers may be beneficial in the management of functional abdominal pain disorders (FAPDs) in children and adolescents if triggers can be identified. Triggers may be identified by asking about aggravating and relieving factors or by asking the patient to keep a pain diary. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'History'</a>.)</p><p></p><p class="headingAnchor" id="H495530705"><span class="h2">Dietary triggers</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eating in general</strong> – Among patients with FAPDs and visceral hypersensitivity, the act of eating may be associated with onset of pain. It is common for patients, particularly adolescents, to skip meals to avoid symptoms [<a href="#rid70">70</a>]. This practice should trigger suspicion of an eating disorder when the adolescent also has weight loss and constipation. (See  <a class="medical medical_review" href="/z/d/html/14705.html" rel="external">"Anorexia nervosa in adults and adolescents: Medical complications and their management", section on 'Gastrointestinal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific triggers</strong> – We suggest not routinely restricting the diet of children with FAPDs. By definition, children with FAPDs do not have food allergy, which is typically excluded by the absence of other characteristic findings (eg, urticaria, oropharyngeal symptoms). High-certainty evidence of benefit is lacking, and restricted diets may result in nutrient deficiencies [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/2398.html" rel="external">"Clinical manifestations of food allergy: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/2396.html" rel="external">"Diagnostic evaluation of IgE-mediated food allergy"</a>.)</p><p></p><p class="bulletIndent1">However, on a case-by-case basis, if there seems to be a correlation of symptoms with specific food triggers, a time-limited trial of elimination of the trigger(s) may be warranted [<a href="#rid9">9</a>]. Specific dietary triggers include citrus, caffeine, <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">sorbitol</a> (found in sugar-free candy and gum), and gas-producing foods (eg, beans, onions, celery, carrots, raisins, bananas, apricots, prunes, Brussels sprouts, wheat germ) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">It can be difficult to identify specific dietary triggers in children with FAPDs. Although they identify a variety of foods that exacerbate their symptoms (spicy foods, cow's milk, pizza, fried foods, fast foods, sodas, cheese, ice cream, and salsa are most commonly reported), they do not consistently identify a single food or ingredient (eg, wheat, lactose) [<a href="#rid73">73,74</a>]. In addition, dietary restriction may result in nutrient deficiencies; clinicians must take care to ensure that the restricted diet provides adequate nutrition. Consultation with a dietitian may be warranted.</p><p></p><p class="bulletIndent1">Potential specific triggers include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lactose</strong> – A trial of a lactose-free diet may be warranted if symptoms are consistent with lactose intolerance (eg, cramping pain, bloating, or gas related to ingestion of lactose). A lactose-free diet can be achieved by eliminating milk and milk products or by using lactase enzyme replacements. Patients who eliminate milk and milk products should be educated about adequate calcium and vitamin D intake. Lactose should be reintroduced if symptoms do not improve after two weeks of lactose elimination. Lactose avoidance may be continued in children whose symptoms improve during a lactose-free diet. For those patients in whom the benefit of lactose avoidance is unclear, it may be helpful to do a lactose hydrogen breath test. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management", section on 'Malabsorption testing by hydrogen breath test'</a>.)</p><p></p><p class="bulletIndent2">Whether a lactose-free diet decreases the frequency of pain attacks for children and adolescents with FAPDs is uncertain [<a href="#rid75">75</a>]. Studies evaluating the effects of a lactose-free or low-lactose diet in children with FAPDs have had mixed results [<a href="#rid76">76-79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gluten/wheat</strong> – Patients with FAPDs may attribute their symptoms to carbohydrates other than lactose [<a href="#rid80">80</a>]. Gluten-free diets have become popular with increased concerns about the role of gluten sensitivity or celiac disease in chronic abdominal pain [<a href="#rid70">70,81</a>]. However, celiac disease is a rare cause of chronic abdominal pain in children. In a prospective study, only 1 out of 227 children ≥5 years of age with recurrent abdominal pain was found to have celiac disease [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2">Nonceliac gluten sensitivity (also called wheat intolerance syndrome) may be associated with gastrointestinal symptoms in a small subset of children [<a href="#rid83">83</a>]. In a prospective multicenter study in 1114 children with chronic gastrointestinal symptoms, symptoms correlated with gluten in 36 (3.3 percent); among the 28 who underwent randomized double-blind, placebo-controlled crossover gluten challenge, 11 reacted positively [<a href="#rid84">84</a>]. Wheat and gluten have also been associated with gastrointestinal symptoms in adult irritable bowel syndrome (IBS) patients without evidence of celiac disease [<a href="#rid85">85,86</a>]. Further understanding of the prevalence and mechanism of nonceliac wheat sensitivity is needed before gluten avoidance can be recommended for children and adolescents with FAPDs. Randomized trials of gluten avoidance in children with FAPDs are lacking [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FODMAPs</strong> – FODMAPs are another group of carbohydrates that are considered potential triggers of FAPDs. FODMAPs are short-chain carbohydrates that are poorly absorbed by the gastrointestinal system and can lead to gas production, distention of the large intestine, bloating, and abdominal pain [<a href="#rid79">79</a>]. There is some evidence that a diet low in FODMAPs may be helpful in adults with IBS. (See  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on 'Low FODMAP diet'</a>.)</p><p></p><p class="bulletIndent2">However, information on the role of FODMAPs in FAPDs in children is limited [<a href="#rid14">14</a>]. Several studies that focused on intolerance to fructose in children with FAPDs reported improvement in pain with fructose restriction, but these studies did not include a control group [<a href="#rid88">88-90</a>]. In a randomized crossover trial of 48 hours of a low- versus high-FODMAP diet in 33 children (7 to 17 years) with IBS, the low-FODMAP diet was associated with some improvement in gastrointestinal symptoms (eg, bloating, nausea) and decreased breath hydrogen production [<a href="#rid91">91,92</a>]. Mean pain severity scores decreased on both diets compared with baseline.</p><p></p><p class="bulletIndent2">Although there is insufficient evidence for or against the efficacy and safety of routinely using a low-FODMAP diet for the management of children with FAPD [<a href="#rid93">93</a>], excessive gas formation is a potential indication.</p><p></p><p class="bulletIndent2">Dietary restrictions in children should be implemented in consultation with a dietician because they may affect nutritional adequacy [<a href="#rid70">70</a>], be difficult to adhere to, and promote distorted eating in vulnerable children and adolescents. In adults, the low-FODMAP diet typically includes three phases: comprehensive elimination (usually for two to six weeks); reintroduction (during which individual FODMAP carbohydrates are used to determine which ones are most associated with symptoms); and personalization (tailoring the low-FODMAP diet to primarily avoid FODMAP triggers previously identified) [<a href="#rid94">94</a>]. Alternatively, a simplified version of the diet, called a "FODMAP-gentle diet" or "bottom-up approach," that initially excludes only a few foods with high concentrations of FODMAPs and gradually eliminates additional FODMAP products from the diet until the symptoms are alleviated has been proposed in children to avoid over-restriction and/or improve adherence [<a href="#rid93">93</a>].</p><p></p><p class="headingAnchor" id="H67029135"><span class="h2">Anxiety</span><span class="headingEndMark"> — </span>Identification of coexisting anxiety in patients with FAPDs is critical. Anxiety disorders are estimated to affect 42 to 85 percent of pediatric patients with FAPDs [<a href="#rid95">95-97</a>]. It is important to explain to the patient and caregivers that screening for anxiety does not imply that the FAPD is a manifestation of a psychological disorder but rather that anxiety and the FAPD may coexist due to shared causative factors or as a consequence of coping with chronic pain [<a href="#rid37">37</a>]. In addition, there is evidence that anxiety may be associated with higher levels of functional impairment in children and adolescents with FAPDs [<a href="#rid16">16</a>].</p><p>Several nonpharmacologic therapies can be used to try to mitigate the physiologic effects of anxiety, including abdominal pain [<a href="#rid21">21</a>]. (See <a class="local">'Improved coping'</a> above.)</p><p>Nonpharmacologic therapies are an excellent way for caregivers to assess for anxiety and/or depression. Follow-up visits allow the caregivers, primary care provider, and, at times, the adolescent explore anxiety and/or depression as triggers of abdominal pain and nausea. Confirmation of anxiety and/or depression in this context sets the stage for the next step in management (ie, referral to a therapist for evaluation for anxiety/depression). If a therapist is already involved, discussion between the primary care provider and therapist can facilitate decisions regarding the need for medication (eg, selective serotonin reuptake inhibitor [SSRI]) and/or adjustments to counseling and other psychosocial interventions.</p><p>Referral to a psychiatrist is indicated if the therapist suggests medication. Alternatively, the primary care provider may prescribe an SSRI (eg, <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">fluoxetine</a>) if they have experience comanaging anxiety and/or depression in children and adolescents with a therapist. Close follow-up for side effects and response is recommended. (See  <a class="medical medical_review" href="/z/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication"</a>.)</p><p class="headingAnchor" id="H67028267"><span class="h1">MANAGEMENT OF SYMPTOMS</span></p><p class="headingAnchor" id="H285364821"><span class="h2">Abdominal pain</span><span class="headingEndMark"> — </span>Medical interventions that may be combined with general behavioral management strategies for the management of abdominal pain in children with functional abdominal pain disorders (FAPDs) include probiotics, supplementation with water-soluble fiber (eg, <a class="drug drug_pediatric" data-topicid="12749" href="/z/d/drug information/12749.html" rel="external">psyllium</a>/ispaghula husk), or peppermint oil. Although these interventions have not been well established in treatment algorithms, they have low risk of harm and short-term trials are reasonable. These interventions may be tried in any order or combination. We typically start with probiotics in patients with normal bowel movements and probiotics plus fiber in patients with constipation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics</strong> – Probiotics combined with general management strategies may be helpful in the management of abdominal pain, but the mechanism of action is not clear. Alterations to commensal bacterial populations have been implicated in dysmotility, visceral hypersensitivity, abnormal colonic fermentation, and immunologic activation. Probiotics may improve gastrointestinal symptoms by restoring the microbial balance in the gut through metabolic competition with pathogens, by enhancing the intestine's mucosal barrier, or by altering the intestinal inflammatory response [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1">The most effective probiotic strain, dose, or treatment duration has not been established [<a href="#rid99">99,100</a>]. Given that probiotics generally are safe [<a href="#rid101">101</a>], the decision to use a probiotic is typically based on the potential benefits, costs, and patient/family preferences. When the decision is made to try probiotics, we suggest commercial preparations of strains that have some evidence of benefit in gastrointestinal disease (eg, <a class="drug drug_pediatric" data-topicid="13404" href="/z/d/drug information/13404.html" rel="external">Lactobacillus</a> <em>reuteri</em> DSM 17938 at a dose of ≥10<sup>8</sup> colony-forming units per day) [<a href="#rid102">102</a>]. We suggest that the probiotic be tried for four to six weeks before reassessment of symptoms of abdominal pain and/or abnormal bowel movements.</p><p></p><p class="bulletIndent1">A 2023 meta-analysis of six randomized trials in 554 children with FAP found that probiotics were more effective than placebo for treatment success (50 versus 33 percent; risk ratio 1.57, 95% CI 1.05-2.36), based on low-certainty evidence [<a href="#rid100">100</a>]. The analysis was unable to determine whether probiotics are more effective than placebo for complete resolution of pain. It was also unable to distinguish between effectiveness of different probiotics, but most of the data were on <em>L</em>. <em>reuteri</em> or <a class="drug drug_pediatric" data-topicid="13404" href="/z/d/drug information/13404.html" rel="external">Lactobacillus</a> <em>rhamnosus</em> <em>GG</em>. Although no cases of serious adverse events were reported, no conclusions can be drawn due to the low level of certainty due to imprecision from very low numbers and risk of bias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fiber</strong> – For children with FAPDs and altered bowel movements, supplementation with water-soluble fiber may be warranted in addition to general management strategies. The exact mechanisms by which fiber may improve abdominal pain are not well understood but may include modification of intestinal microbiota, altered composition of stool and gas, and/or accelerated gastrointestinal transit [<a href="#rid103">103</a>]. Benefits of fiber supplementation should be weighed against the low but potential risk of increased bloating and pain.</p><p></p><p class="bulletIndent1">The optimal dose, fiber type, and treatment duration for use in children with abdominal pain has not been established. We generally suggest using a water-soluble fiber (eg, <a class="drug drug_pediatric" data-topicid="12749" href="/z/d/drug information/12749.html" rel="external">psyllium</a> hydrophilic mucilloid [ispaghula husk]) at a dose of 1.5 to 12.5 grams per day, depending on the patient's size and baseline dietary intake of fiber. A reasonable target for total dietary fiber intake is the child's age in years plus 5 to 10 grams per day. We continue the trial of fiber supplementation for at least four weeks before determining whether there has been an improvement in abdominal pain frequency and severity.</p><p></p><p class="bulletIndent1">A 2022 systematic review of five randomized trials that compared fiber supplementation with placebo in 385 children ages 4 to 18 years with FAPDs concluded that water-soluble fibers, particularly <a class="drug drug_pediatric" data-topicid="12749" href="/z/d/drug information/12749.html" rel="external">psyllium</a>, may provide a slight benefit [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1">Recommendations regarding fiber intake in children with chronic functional constipation and fecal incontinence are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children", section on 'Fiber'</a> and  <a class="medical medical_review" href="/z/d/html/5873.html" rel="external">"Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment", section on 'Dietary changes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peppermint oil</strong> – Peppermint oil is another intervention that may be helpful in combination with general management strategies in the management of abdominal pain in children with FAPDs [<a href="#rid14">14,105,106</a>]. (See <a class="local">'General management strategies'</a> above.)</p><p></p><p class="bulletIndent1">Although the evidence is limited, peppermint oil is thought to decrease smooth muscle spasms in the gastrointestinal tract [<a href="#rid21">21</a>]. A 2022 systematic review of pharmacologic treatments for FAPDs in children included two randomized controlled trials evaluating two to four weeks of treatment with peppermint oil and found low-certainty evidence that peppermint oil reduced pain severity, duration, and frequency compared with placebo or lactol (<em>Bacillus</em> <em>coagulans</em> plus fructooligosaccharides) [<a href="#rid107">107-109</a>]. No patients discontinued treatment due to adverse events. A 2011 meta-analysis of randomized trials in patients &gt;12 years of age concluded that peppermint oil was effective in the treatment of irritable bowel syndrome (IBS) [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1">Peppermint oil capsules are available commercially. In both of the included trials, peppermint oil was administered as a pH-dependent enteric coated capsule (187 mg three times per day for children weighing &lt;45 kg; 374 mg three times per day for children weighing &gt;45 kg). Excessive intake of peppermint oil may lead to exacerbation of gastroesophageal reflux and has been associated with interstitial nephritis and acute renal failure [<a href="#rid110">110,111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antispasmodics</strong> – Other antispasmodics include drotaverine, mebeverine, <a class="drug drug_general" data-topicid="10111" href="/z/d/drug information/10111.html" rel="external">trimebutine</a>, <a class="drug drug_pediatric" data-topicid="13369" href="/z/d/drug information/13369.html" rel="external">hyoscyamine</a>, and <a class="drug drug_pediatric" data-topicid="13228" href="/z/d/drug information/13228.html" rel="external">dicyclomine</a>. While antispasmodic medications are superior to placebo in the treatment of adults with IBS [<a href="#rid112">112</a>], few studies have evaluated the effectiveness of antispasmodics in the treatment of childhood FAPDs [<a href="#rid108">108,113</a>]. A 2022 systematic review of pharmacologic treatments for FAPDs in children included three randomized controlled trials evaluating three to four weeks of treatment with other antispasmodics (drotaverine, mebeverine, trimebutine) and found low-certainty evidence that these agents improve treatment success and decrease pain episodes [<a href="#rid108">108,114-116</a>]. Three participants discontinued mebeverine for adverse effects (drowsiness, nervousness, nausea), and one participant discontinued drotaverine due to urticaria [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1">The long-term use of other antispasmodic medications in children may be limited by anticholinergic side effects (eg, dry mouth, blurred vision) [<a href="#rid21">21</a>]. Additional studies of safety and efficacy are necessary before antispasmodic medications can be routinely recommended for children with FAPDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interventions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antidepressants</strong> – We suggest not routinely prescribing antidepressants for children and adolescents with FAPDs unless they meet diagnostic criteria for associated depression. (See  <a class="medical medical_review" href="/z/d/html/1224.html" rel="external">"Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis", section on 'Diagnosing depressive disorders'</a>.)</p><p></p><p class="bulletIndent2">A substantial proportion of abdominal pain in functional disorders is believed to be associated with abnormal perception of visceral sensations. Medications initially indicated for the treatment of depression and anxiety have been explored for the management of FAPDs because of their effects on central and enteric nervous system neurotransmitters, such as acetylcholine and serotonin. However, studies of these agents in children and adolescents with FAPDs are limited and it is uncertain whether antidepressants are beneficial in the treatment of FAPDs in children [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13194" href="/z/d/drug information/13194.html" rel="external">Cyproheptadine</a> – Cyproheptadine is a medication with multiple mechanisms, including antihistaminic, anticholinergic, and antiserotonergic properties as well as possible calcium channel blockade effects. It has been used in appetite stimulation and prevention of pain and vomiting in abdominal migraine and cyclic vomiting syndrome. In retrospective studies, cyproheptadine has been reported to be safe and effective for the treatment of FAPDs and dyspeptic symptoms in children [<a href="#rid118">118,119</a>]. In a randomized trial of 29 children and adolescents with FAPDs, 86 percent of the group treated with cyproheptadine for two weeks had improvement or resolution of abdominal pain compared with 35.7 percent in the placebo group [<a href="#rid120">120</a>]. These results need to be confirmed with larger, additional trials before cyproheptadine can be routinely recommended for the treatment of FAPDs [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Auricular neurostimulation therapy</strong> – In auricular neurostimulation therapy, percutaneous electrical nerve field stimulation (PENFS) is administered through a noninvasive device that is worn behind the ear to target central pain pathways involved in pain amplification [<a href="#rid121">121</a>]. In a randomized sham-controlled trial in 115 adolescents, auricular neurostimulation reduced abdominal pain severity, frequency, and duration with no serious adverse effects in adolescents with FAPDs [<a href="#rid122">122</a>]. In another randomized sham-controlled trial in 50 adolescents with IBS, auricular neurostimulation reduced abdominal pain scores and improved overall well-being [<a href="#rid121">121</a>]. In addition to improvements in self-reported symptoms of abdominal pain and nausea, PENFS has been associated with changes in visceral sensitivity using a water load task, actigraphic and subjective sleep measures, and other psychological factors like catastrophizing and somatic complaints [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2">Although these findings are promising and the US Food and Drug Administration has granted permission to market the device for relief of FAP in 11- to 18-year-old adolescents with IBS, additional studies are necessary to confirm the results, determine the optimal setting and duration of treatment, and determine the optimal target population before PENFS can be routinely recommended for children with FAPDs [<a href="#rid14">14,122,124,125</a>].</p><p></p><p class="headingAnchor" id="H67028274"><span class="h2">Dyspepsia</span><span class="headingEndMark"> — </span>Dyspepsia is pain or discomfort that is centered in the epigastric region or upper abdomen. Discomfort may be characterized by fullness, early satiety, bloating, nausea, retching, or vomiting [<a href="#rid7">7</a>]. The pain or discomfort may be exacerbated by eating. Dyspepsia is the predominant symptom in children with functional dyspepsia  (<a class="graphic graphic_table graphicRef71435" href="/z/d/graphic/71435.html" rel="external">table 2</a>).</p><p>We suggest the following interventions for symptomatic management of functional dyspepsia [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Small, frequent meals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of foods, beverages, and medications that aggravate symptoms (eg, high-fat foods, caffeinated beverages, nonsteroidal antiinflammatory drugs) [<a href="#rid20">20</a>] (see <a class="local">'Dietary triggers'</a> above)</p><p></p><p>We suggest not routinely using pharmacologic therapy (eg, H2 blockers, proton pump inhibitors) for children and adolescents with functional dyspepsia. A 2022 systematic review of pharmacologic therapy for FAPDs in children included only one randomized trial with inconclusive results [<a href="#rid108">108,126</a>]. However, for children and adolescents with severe symptoms unresponsive to nonpharmacologic therapies, a trial of an H2 blocker (<a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a>, <a class="drug drug_pediatric" data-topicid="13295" href="/z/d/drug information/13295.html" rel="external">famotidine</a>; <a class="drug drug_pediatric" data-topicid="12759" href="/z/d/drug information/12759.html" rel="external">ranitidine</a> has been withdrawn from the market in the United States and Australia [<a href="#rid127">127,128</a>]) or a proton pump inhibitor (<a class="drug drug_pediatric" data-topicid="12543" href="/z/d/drug information/12543.html" rel="external">lansoprazole</a>, <a class="drug drug_pediatric" data-topicid="13281" href="/z/d/drug information/13281.html" rel="external">esomeprazole</a>) for four to six weeks may be warranted [<a href="#rid9">9,129,130</a>]. The medication should be discontinued if there is no improvement.</p><p>We suggest not routinely using prokinetic agents (eg, <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">metoclopramide</a>, <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">domperidone</a>, <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a>) in the treatment of children and adolescents with FAPDs. There is little evidence of efficacy and potential for adverse effects, particularly with metoclopramide and domperidone [<a href="#rid9">9,21,131</a>].</p><p class="headingAnchor" id="H67028309"><span class="h2">Diarrhea</span><span class="headingEndMark"> — </span>Diarrhea may be the predominant symptom in children with IBS  (<a class="graphic graphic_table graphicRef71435" href="/z/d/graphic/71435.html" rel="external">table 2</a>). Children and adolescents whose diarrhea consists of ≥3 loose or watery stools per day for more than two weeks (which is an alarm symptom) require evaluation for organic disease. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Patients with alarm findings'</a>.)</p><p>From a practical standpoint, it may be helpful for the clinician to provide a note to the school requesting that the child or adolescent with FAPD and diarrhea be allowed to use the bathroom whenever necessary [<a href="#rid9">9,12</a>]. In addition, it is important for the patient to maintain adequate fluid intake.</p><p>We suggest not routinely restricting the diet of children with FAPD and diarrhea. However, on a case-by-case basis, if there seems to be a correlation of diarrhea with a specific food trigger (eg, lactose, <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">sorbitol</a>), a time-limited trial of elimination of the trigger may be warranted [<a href="#rid9">9</a>]. (See <a class="local">'Dietary triggers'</a> above.)</p><p>We suggest not routinely using antimotility agents for children or adolescents with FAPD and diarrhea. The diarrhea associated with FAPDs is typically of short duration, and antimotility agents generally are not recommended for the management of other types of diarrhea (eg, infectious, antibiotic-associated) in children.</p><p class="headingAnchor" id="H67028316"><span class="h2">Constipation</span><span class="headingEndMark"> — </span>Identification of underlying constipation is critical for patients with FAPD. The treatment of constipation in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5873.html" rel="external">"Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment", section on 'Treatment of constipation in children'</a>.)</p><p class="headingAnchor" id="H2429456694"><span class="h2">Unproven interventions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Open-label placebo</strong> – In placebo-controlled trials in children with FAPDs, the response to placebo is substantial [<a href="#rid19">19</a>], which may be related to the natural history of improvement over time, regression to the mean, methodologic factors, and contextual factors (eg, expectations and conditioning) [<a href="#rid14">14</a>]. Although it was traditionally believed that blinding of patients was necessary to elicit a placebo response, studies in adult patients with IBS suggest a placebo response even when the placebo is administered openly [<a href="#rid132">132,133</a>]. In a subsequent crossover trial in which 30 children and adolescents with FAPDs were randomly assigned to three weeks of open-label placebo (an inert oral suspension) or a three-week control period, mean pain scores (39.9 versus 45.0) and mean number of doses of rescue medication (2.0 versus 3.8) were lower during the open-label placebo period [<a href="#rid134">134</a>]. These results suggest that open-label placebo may reduce pain in children with FAPDs, but additional studies are necessary before open-label placebo can be recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other unproven interventions</strong> – A number of other interventions are used in adults with pain-predominant functional gastrointestinal disorders or have been tried in children with FAP but lack clear evidence of benefit in randomized trials. These include <a class="drug drug_pediatric" data-topicid="94528" href="/z/d/drug information/94528.html" rel="external">rifaximin</a> [<a href="#rid135">135,136</a>], <a class="drug drug_pediatric" data-topicid="141759" href="/z/d/drug information/141759.html" rel="external">linaclotide</a>, <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a>, otilonium bromide (available outside of the United States), fennel, licorice, ginger, and Iberogast (an herbal therapy) [<a href="#rid137">137</a>]. (See  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Children and adolescents with functional abdominal pain disorders (FAPDs) require regular follow-up to maintain the therapeutic relationship, provide continued education and reassurance, monitor the response to intervention, and monitor the development of alarm findings  (<a class="graphic graphic_table graphicRef90721" href="/z/d/graphic/90721.html" rel="external">table 1</a>) [<a href="#rid11">11,12,39</a>].</p><p>Children with persistent abdominal pain that affects patient and family function may benefit from referral to a mental health provider, other specialist, or multidisciplinary clinic [<a href="#rid24">24</a>]. (See <a class="local">'Indications for referral'</a> below.)</p><p>Children who develop alarm findings  (<a class="graphic graphic_table graphicRef90721" href="/z/d/graphic/90721.html" rel="external">table 1</a>) require evaluation for organic disease. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Patients with alarm findings'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INDICATIONS FOR REFERRAL</span></p><p class="bulletIndent1"><span class="glyph">●</span>Alarm findings – Children who develop alarm findings  (<a class="graphic graphic_table graphicRef90721" href="/z/d/graphic/90721.html" rel="external">table 1</a>) may require referral to a gastroenterologist or other specialist for evaluation and/or management. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Patients with alarm findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain-associated disability – Children with abdominal pain-associated disability (eg, missed school or extracurricular activities, anxiety, depression) may benefit from referral to a mental health provider for counseling or therapy and rehabilitation, including cognitive behavioral therapy (CBT).</p><p></p><p class="bulletIndent1">Referral to a developmental-behavioral pediatrician (for younger children), adolescent medicine specialist (for teenagers), mental health provider, or multidisciplinary clinic may be helpful in providing strategies for return to activities of daily living and avoiding ongoing pain-induced disability [<a href="#rid10">10,12,24,75</a>].</p><p></p><p class="bulletIndent1">Some patients and families, particularly those who continue to focus on the search for an organic etiology, may be resistant to referral to a therapist or counselor. The pediatric care provider can facilitate referral by explaining to the family their limitations in management without further assistance from a therapist. The provider should discuss the potential benefit to the family from counseling sessions with a therapist who can help the child cope with the pain and can support the necessary changes in the child's life (eg, return to school).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Refractory constipation – Children with constipation that does not respond to primary care interventions may benefit from referral to a gastroenterologist. (See  <a class="medical medical_review" href="/z/d/html/5873.html" rel="external">"Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Functional abdominal pain disorders (FAPDs) resolve in the majority of children [<a href="#rid16">16,17,138</a>]. In a systematic review of 18 prospective studies including 1331 children with chronic abdominal pain, abdominal pain persisted in 29.1 percent (95% CI 28.1-30.2) at median follow-up of five years (range 1 to 29) [<a href="#rid17">17</a>]. In a prospective study of 132 children with FAPDs followed in a gastroenterology clinic, symptoms improved in approximately 85 percent of patients by two months and improvement was maintained at one and five years [<a href="#rid16">16</a>].</p><p>Factors associated with improvement of abdominal pain in observational studies include caregiver acceptance of a biopsychosocial model of illness, low levels of symptoms and impairment at the time of presentation, and rapid improvement in symptoms in patients with high levels of symptoms and impairment at the time of presentation [<a href="#rid16">16,23</a>].</p><p>Factors associated with persistent functional pain include caregiver modeling and reinforcement of the sick role, family members with chronic pain disorders, age younger than six years at the time of diagnosis, more than six months' duration of pain before seeking treatment, negative life events, and increased symptoms of anxiety and depression [<a href="#rid16">16,20,21,139</a>].</p><p>Some longitudinal studies suggest that children with FAP-not otherwise specified (FAP-NOS) go on to have irritable bowel syndrome (IBS) as adults [<a href="#rid140">140-142</a>]. In a longitudinal study of 392 patients diagnosed with FAP-NOS following a specialty clinic evaluation at age 8 to 16 years, 41 percent met symptom criteria for a functional gastrointestinal disorder at follow-up 5 to 15 years later (average 9.2 years) [<a href="#rid142">142</a>]. IBS and functional dyspepsia were the most frequent functional gastrointestinal disorders. After controlling for age, sex, and severity of abdominal pain at the time of diagnosis, a functional gastrointestinal disorder at follow-up was associated with extraintestinal somatic and depressive symptoms.</p><p>Other prospective studies indicate that children with a history of FAP-NOS are at risk for anxiety or depression in adolescence and adulthood [<a href="#rid35">35,143-145</a>]. In a prospective study in which 322 children with FAPDs were followed to young adulthood (mean age 20 years), the lifetime risk of anxiety and depression were 51 and 40 percent (versus 20 and 16 percent in controls) [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1386448418"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121705.html" rel="external">"Society guideline links: Chronic abdominal pain in children"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1200.html" rel="external">"Patient education: Chronic abdominal pain in children and adolescents (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Functional abdominal pain disorders (FAPDs) can be diagnosed in children who have all of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic (≥2 months) abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>No alarm findings  (<a class="graphic graphic_table graphicRef90721" href="/z/d/graphic/90721.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Normal physical examination</p><p class="bulletIndent2"><span class="glyph">•</span>Stool sample negative for occult blood</p><p></p><p class="bulletIndent1">Several functional gastrointestinal disorders of childhood have recognizable patterns of symptoms, including irritable bowel syndrome (IBS), functional dyspepsia, and abdominal migraine  (<a class="graphic graphic_table graphicRef71435" href="/z/d/graphic/71435.html" rel="external">table 2</a>). (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management approach</strong> – The goal of management of FAPDs in children and adolescents is return to normal function rather than complete elimination of pain (a rehabilitation approach). Management is individualized according to child and family behavior, triggers, and symptoms. Most cases can be managed in the primary care setting. (See <a class="local">'Management approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General management strategies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FAPDs are best treated in the context of a biopsychosocial model of care  (<a class="graphic graphic_figure graphicRef90722" href="/z/d/graphic/90722.html" rel="external">figure 1</a>). The patient and family must believe that their complaints and concerns are taken seriously. Establishing a therapeutic relationship, patient and family education, and a plan for return to school are important components of management. (See <a class="local">'Therapeutic relationship'</a> above and <a class="local">'Patient education'</a> above and <a class="local">'Return to school'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Return to normal function is facilitated by reinforcement of nonpain (healthy or adaptive) behaviors and avoiding reinforcement of pain or pain (sick, illness, maladaptive) behaviors. (See <a class="local">'Behavior modification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest psychological interventions (eg, relaxation, distraction, guided imagery, cognitive behavioral therapy [CBT]  (<a class="graphic graphic_table graphicRef90731" href="/z/d/graphic/90731.html" rel="external">table 3</a>)) to improve coping and decrease stress/anxiety in children and adolescents with FAPDs (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Improved coping'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary triggers</strong> – We suggest not routinely restricting the diet of children and adolescents with FAPDs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, on a case-by-case basis, a time-limited trial of avoidance of specific dietary triggers (eg, lactose, <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">sorbitol</a>) may be warranted. (See <a class="local">'Dietary triggers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of symptoms</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medical interventions that may be combined with behavioral interventions include a trial of probiotics, supplementation with water-soluble fiber (eg, <a class="drug drug_pediatric" data-topicid="12749" href="/z/d/drug information/12749.html" rel="external">psyllium</a>/ispaghula husk), or peppermint oil. These interventions may be tried in any order or combination. We typically start with probiotics in patients with normal bowel movements and probiotics plus fiber in patients with constipation. (See <a class="local">'Abdominal pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest small frequent meals and avoidance of foods, beverages, and medications that aggravate symptoms rather than pharmacologic therapy for the initial management of functional dyspepsia (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Dyspepsia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest not routinely using antimotility agents for children or adolescents with FAP and diarrhea (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Diarrhea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up and indications for referral</strong> – Regular follow-up is necessary to maintain the therapeutic relationship, provide continued education and reassurance, monitor the response to intervention, and monitor the development of alarm findings. (See <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1">Children with persistent abdominal pain that affects patient and family function may benefit from referral to a mental health provider or other specialist. Children who develop alarm findings  (<a class="graphic graphic_table graphicRef90721" href="/z/d/graphic/90721.html" rel="external">table 1</a>) require evaluation for organic disease. (See <a class="local">'Indications for referral'</a> above and  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Patients with alarm findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – FAPDs resolve over several months in the majority of children. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Boyle JT, Hamel-Lambert J. Biopsychosocial issues in functional abdominal pain. Pediatr Ann 2001; 30:32.</a></li><li><a class="nounderline abstract_t">Di Lorenzo C, Youssef NN, Sigurdsson L, et al. Visceral hyperalgesia in children with functional abdominal pain. J Pediatr 2001; 139:838.</a></li><li><a class="nounderline abstract_t">Duarte MA, Goulart EM, Penna FJ. Pressure pain threshold in children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr 2000; 31:280.</a></li><li><a class="nounderline abstract_t">Faure C, Wieckowska A. Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders. J Pediatr 2007; 150:66.</a></li><li><a class="nounderline abstract_t">Olafsdottir E, Gilja OH, Aslaksen A, et al. Impaired accommodation of the proximal stomach in children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr 2000; 30:157.</a></li><li><a class="nounderline abstract_t">Alfvén G. The pressure pain threshold (PPT) of certain muscles in children suffering from recurrent abdominal pain of non-organic origin. An algometric study. Acta Paediatr 1993; 82:481.</a></li><li><a class="nounderline abstract_t">Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Subcommittee on Chronic Abdominal Pain. Chronic abdominal pain in children. Pediatrics 2005; 115:812.</a></li><li><a class="nounderline abstract_t">McFerron BA, Waseem S. Chronic recurrent abdominal pain. Pediatr Rev 2012; 33:509.</a></li><li><a class="nounderline abstract_t">Banez GA. Chronic abdominal pain in children: what to do following the medical evaluation. Curr Opin Pediatr 2008; 20:571.</a></li><li><a class="nounderline abstract_t">Wright NJ, Hammond PJ, Curry JI. Chronic abdominal pain in children: help in spotting the organic diagnosis. Arch Dis Child Educ Pract Ed 2013; 98:32.</a></li><li><a class="nounderline abstract_t">Walker LS, Beck J, Anderson J. Functional abdominal separation anxiety: helping the child return to school. Pediatr Ann 2009; 38:267.</a></li><li><a class="nounderline abstract_t">Primavera G, Amoroso B, Barresi A, et al. Clinical utility of Rome criteria managing functional gastrointestinal disorders in pediatric primary care. Pediatrics 2010; 125:e155.</a></li><li><a class="nounderline abstract_t">Rexwinkel R, Vlieger AM, Saps M, et al. A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. Eur J Pediatr 2022; 181:2603.</a></li><li><a class="nounderline abstract_t">Walker LS, Stone AL, Han GT, et al. Internet-delivered cognitive behavioral therapy for youth with functional abdominal pain: a randomized clinical trial testing differential efficacy by patient subgroup. Pain 2021; 162:2945.</a></li><li><a class="nounderline abstract_t">Mulvaney S, Lambert EW, Garber J, Walker LS. Trajectories of symptoms and impairment for pediatric patients with functional abdominal pain: a 5-year longitudinal study. J Am Acad Child Adolesc Psychiatry 2006; 45:737.</a></li><li><a class="nounderline abstract_t">Gieteling MJ, Bierma-Zeinstra SM, Passchier J, Berger MY. Prognosis of chronic or recurrent abdominal pain in children. J Pediatr Gastroenterol Nutr 2008; 47:316.</a></li><li><a class="nounderline abstract_t">Martin AE, Newlove-Delgado TV, Abbott RA, et al. Pharmacological interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017; 3:CD010973.</a></li><li><a class="nounderline abstract_t">Hoekman DR, Zeevenhooven J, van Etten-Jamaludin FS, et al. The Placebo Response in Pediatric Abdominal Pain-Related Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis. J Pediatr 2017; 182:155.</a></li><li><a class="nounderline abstract_t">Boyle JT. Recurrent abdominal pain: an update. Pediatr Rev 1997; 18:310.</a></li><li><a class="nounderline abstract_t">Chiou E, Nurko S. Functional abdominal pain and irritable bowel syndrome in children and adolescents. Therapy 2011; 8:315.</a></li><li><a class="nounderline abstract_t">Sood MR. Treatment approaches to irritable bowel syndrome. Pediatr Ann 2009; 38:272.</a></li><li><a class="nounderline abstract_t">Crushell E, Rowland M, Doherty M, et al. Importance of parental conceptual model of illness in severe recurrent abdominal pain. Pediatrics 2003; 112:1368.</a></li><li><a class="nounderline abstract_t">Chu AS, Torres L, Kao G, et al. Multidisciplinary Care for Refractory Pediatric Functional Abdominal Pain Decreases Emergency and Inpatient Utilization. J Pediatr Gastroenterol Nutr 2022; 74:248.</a></li><li><a class="nounderline abstract_t">Beinvogl B, Burch E, Snyder J, et al. Multidisciplinary Treatment Reduces Pain and Increases Function in Children With Functional Gastrointestinal Disorders. Clin Gastroenterol Hepatol 2019; 17:994.</a></li><li class="breakAll">Palermo TM, Zeltzer LK. Recurrent and chronic pain. In: Developmental-Behavioral Pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.547.</li><li><a class="nounderline abstract_t">Schurman JV, Friesen CA. Integrative treatment approaches: family satisfaction with a multidisciplinary paediatric Abdominal Pain Clinic. Int J Integr Care 2010; 10.</a></li><li><a class="nounderline abstract_t">Barad AV, Saps M. Factors influencing functional abdominal pain in children. Curr Gastroenterol Rep 2008; 10:294.</a></li><li class="breakAll">Assesment and management of children with chronic pain. A position statement from the American Pain Society. Available at: http://www.americanpainsociety.org/uploads/pdfs/aps12-pcp.pdf (Accessed on August 15, 2013).</li><li><a class="nounderline abstract_t">Gottsegen D. Complementary, holistic, and integrative medicine: recurrent abdominal pain. Pediatr Rev 2010; 31:e36.</a></li><li><a class="nounderline abstract_t">Drossman DA. Functional abdominal pain syndrome. Clin Gastroenterol Hepatol 2004; 2:353.</a></li><li><a class="nounderline abstract_t">Schechter NL, Nurko S. Unintentional Symptom Intensification by Doctors. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Drossman DA. Redux: do little bellyachers grow up to become big bellyachers? Clin Gastroenterol Hepatol 2014; 12:2033.</a></li><li><a class="nounderline abstract_t">Cottrell DJ. Fifteen-minute consultation: Medically unexplained symptoms. Arch Dis Child Educ Pract Ed 2016; 101:114.</a></li><li><a class="nounderline abstract_t">Shelby GD, Shirkey KC, Sherman AL, et al. Functional abdominal pain in childhood and long-term vulnerability to anxiety disorders. Pediatrics 2013; 132:475.</a></li><li><a class="nounderline abstract_t">Allison MA, Attisha E, COUNCIL ON SCHOOL HEALTH. The Link Between School Attendance and Good Health. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Cunningham NR, Lynch-Jordan A, Mezoff AG, et al. Importance of addressing anxiety in youth with functional abdominal pain: suggested guidelines for physicians. J Pediatr Gastroenterol Nutr 2013; 56:469.</a></li><li><a class="nounderline abstract_t">Levy RL, Langer SL, Walker LS, et al. Twelve-month follow-up of cognitive behavioral therapy for children with functional abdominal pain. JAMA Pediatr 2013; 167:178.</a></li><li><a class="nounderline abstract_t">Brett T, Rowland M, Drumm B. An approach to functional abdominal pain in children and adolescents. Br J Gen Pract 2012; 62:386.</a></li><li><a class="nounderline abstract_t">Walker LS, Williams SE, Smith CA, et al. Parent attention versus distraction: impact on symptom complaints by children with and without chronic functional abdominal pain. Pain 2006; 122:43.</a></li><li><a class="nounderline abstract_t">Compas BE, Connor-Smith JK, Saltzman H, et al. Coping with stress during childhood and adolescence: problems, progress, and potential in theory and research. Psychol Bull 2001; 127:87.</a></li><li><a class="nounderline abstract_t">Fisher E, Law E, Dudeney J, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev 2018; 9:CD003968.</a></li><li><a class="nounderline abstract_t">Abbott RA, Martin AE, Newlove-Delgado TV, et al. Psychosocial interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017; 1:CD010971.</a></li><li><a class="nounderline abstract_t">Gordon M, Sinopoulou V, Tabbers M, et al. Psychosocial Interventions for the Treatment of Functional Abdominal Pain Disorders in Children: A Systematic Review and Meta-analysis. JAMA Pediatr 2022; 176:560.</a></li><li><a class="nounderline abstract_t">Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC, et al. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007; 133:1430.</a></li><li><a class="nounderline abstract_t">van Tilburg MA, Chitkara DK, Palsson OS, et al. Audio-recorded guided imagery treatment reduces functional abdominal pain in children: a pilot study. Pediatrics 2009; 124:e890.</a></li><li><a class="nounderline abstract_t">Rutten JM, Reitsma JB, Vlieger AM, Benninga MA. Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review. Arch Dis Child 2013; 98:252.</a></li><li><a class="nounderline abstract_t">Sanders MR, Shepherd RW, Cleghorn G, Woolford H. The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care. J Consult Clin Psychol 1994; 62:306.</a></li><li><a class="nounderline abstract_t">Sanders MR, Rebgetz M, Morrison M, et al. Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects. J Consult Clin Psychol 1989; 57:294.</a></li><li><a class="nounderline abstract_t">Robins PM, Smith SM, Glutting JJ, Bishop CT. A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain. J Pediatr Psychol 2005; 30:397.</a></li><li><a class="nounderline abstract_t">Gerik SM. Pain management in children: developmental considerations and mind-body therapies. South Med J 2005; 98:295.</a></li><li><a class="nounderline abstract_t">Sprenger L, Gerhards F, Goldbeck L. Effects of psychological treatment on recurrent abdominal pain in children - a meta-analysis. Clin Psychol Rev 2011; 31:1192.</a></li><li><a class="nounderline abstract_t">Youssef NN, Rosh JR, Loughran M, et al. Treatment of functional abdominal pain in childhood with cognitive behavioral strategies. J Pediatr Gastroenterol Nutr 2004; 39:192.</a></li><li><a class="nounderline abstract_t">Palermo TM, Eccleston C, Lewandowski AS, et al. Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review. Pain 2010; 148:387.</a></li><li><a class="nounderline abstract_t">Bursch B. Psychological/cognitive behavioral treatment of childhood functional abdominal pain and irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2008; 47:706.</a></li><li class="breakAll">Olness KN, Kohen DP. Hypnosis and Hypnotherapy With Children, 3rd ed, Guilford Press, 1996.</li><li><a class="nounderline abstract_t">Rutten JMTM, Vlieger AM, Frankenhuis C, et al. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial. JAMA Pediatr 2017; 171:470.</a></li><li><a class="nounderline abstract_t">Weydert JA, Shapiro DE, Acra SA, et al. Evaluation of guided imagery as treatment for recurrent abdominal pain in children: a randomized controlled trial. BMC Pediatr 2006; 6:29.</a></li><li><a class="nounderline abstract_t">Gulewitsch MD, Müller J, Hautzinger M, Schlarb AA. Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial. Eur J Pediatr 2013; 172:1043.</a></li><li><a class="nounderline abstract_t">Vlieger AM, Rutten JM, Govers AM, et al. Long-term follow-up of gut-directed hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome. Am J Gastroenterol 2012; 107:627.</a></li><li><a class="nounderline abstract_t">Rexwinkel R, Bovendeert JFM, Rutten JMTM, et al. Long-Term Follow-up of Individual Therapist Delivered and Standardized Hypnotherapy Recordings in Pediatric Irritable Bowel Syndrome or Functional Abdominal Pain. J Pediatr Gastroenterol Nutr 2022; 75:24.</a></li><li><a class="nounderline abstract_t">Lalouni M, Ljótsson B, Bonnert M, et al. Clinical and Cost Effectiveness of Online Cognitive Behavioral Therapy in Children With Functional Abdominal Pain Disorders. Clin Gastroenterol Hepatol 2019; 17:2236.</a></li><li><a class="nounderline abstract_t">Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 1998; 37:26.</a></li><li><a class="nounderline abstract_t">van der Veek SM, de Haan E, Derkx H, et al. Psychological factors addressed in cognitive behaviour therapy for paediatric functional abdominal pain: Which are most important to target? J Health Psychol 2019; 24:1282.</a></li><li><a class="nounderline abstract_t">Korterink JJ, Ockeloen LE, Hilbink M, et al. Yoga Therapy for Abdominal Pain-Related Functional Gastrointestinal Disorders in Children: A Randomized Controlled Trial. J Pediatr Gastroenterol Nutr 2016; 63:481.</a></li><li><a class="nounderline abstract_t">Brands MM, Purperhart H, Deckers-Kocken JM. A pilot study of yoga treatment in children with functional abdominal pain and irritable bowel syndrome. Complement Ther Med 2011; 19:109.</a></li><li><a class="nounderline abstract_t">Kuttner L, Chambers CT, Hardial J, et al. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag 2006; 11:217.</a></li><li><a class="nounderline abstract_t">Evans S, Lung KC, Seidman LC, et al. Iyengar yoga for adolescents and young adults with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2014; 59:244.</a></li><li><a class="nounderline abstract_t">Högström S, Philipson A, Ekstav L, et al. Dance and yoga reduced functional abdominal pain in young girls: A randomized controlled trial. Eur J Pain 2022; 26:336.</a></li><li><a class="nounderline abstract_t">van Tilburg MA, Felix CT. Diet and functional abdominal pain in children and adolescents. J Pediatr Gastroenterol Nutr 2013; 57:141.</a></li><li><a class="nounderline abstract_t">Newlove-Delgado TV, Martin AE, Abbott RA, et al. Dietary interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017; 3:CD010972.</a></li><li><a class="nounderline abstract_t">Portincasa P, Bonfrate L, de Bari O, et al. Irritable bowel syndrome and diet. Gastroenterol Rep (Oxf) 2017; 5:11.</a></li><li><a class="nounderline abstract_t">Carlson MJ, Moore CE, Tsai CM, et al. Child and parent perceived food-induced gastrointestinal symptoms and quality of life in children with functional gastrointestinal disorders. J Acad Nutr Diet 2014; 114:403.</a></li><li><a class="nounderline abstract_t">Chumpitazi BP. Update on Dietary Management of Childhood Functional Abdominal Pain Disorders. Gastroenterol Clin North Am 2018; 47:715.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Subcommittee on Chronic Abdominal Pain, North American Society for Pediatric Gastroenterology Hepatology, and Nutrition. Chronic abdominal pain in children. Pediatrics 2005; 115:e370.</a></li><li><a class="nounderline abstract_t">Lebenthal E, Rossi TM, Nord KS, Branski D. Recurrent abdominal pain and lactose absorption in children. Pediatrics 1981; 67:828.</a></li><li><a class="nounderline abstract_t">Dearlove J, Dearlove B, Pearl K, Primavesi R. Dietary lactose and the child with abdominal pain. Br Med J (Clin Res Ed) 1983; 286:1936.</a></li><li><a class="nounderline abstract_t">Gremse DA, Greer AS, Vacik J, DiPalma JA. Abdominal pain associated with lactose ingestion in children with lactose intolerance. Clin Pediatr (Phila) 2003; 42:341.</a></li><li><a class="nounderline abstract_t">Chumpitazi BP, Shulman RJ. Dietary Carbohydrates and Childhood Functional Abdominal Pain. Ann Nutr Metab 2016; 68 Suppl 1:8.</a></li><li><a class="nounderline abstract_t">Simrén M, Månsson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63:108.</a></li><li><a class="nounderline abstract_t">Francavilla R, Cristofori F, Castellaneta S, et al. Clinical, serologic, and histologic features of gluten sensitivity in children. J Pediatr 2014; 164:463.</a></li><li><a class="nounderline abstract_t">Hyams JS, Treem WR, Justinich CJ, et al. Characterization of symptoms in children with recurrent abdominal pain: resemblance to irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1995; 20:209.</a></li><li><a class="nounderline abstract_t">Jericho H, Assiri A, Guandalini S. Celiac Disease and Wheat Intolerance Syndrome: A Critical Update and Reappraisal. J Pediatr Gastroenterol Nutr 2017; 64:15.</a></li><li><a class="nounderline abstract_t">Francavilla R, Cristofori F, Verzillo L, et al. Randomized Double-Blind Placebo-Controlled Crossover Trial for the Diagnosis of Non-Celiac Gluten Sensitivity in Children. Am J Gastroenterol 2018; 113:421.</a></li><li><a class="nounderline abstract_t">Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107:1898.</a></li><li><a class="nounderline abstract_t">Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508.</a></li><li><a class="nounderline abstract_t">Rutten JM, Korterink JJ, Venmans LM, et al. Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review. Pediatrics 2015; 135:522.</a></li><li><a class="nounderline abstract_t">Gomara RE, Halata MS, Newman LJ, et al. Fructose intolerance in children presenting with abdominal pain. J Pediatr Gastroenterol Nutr 2008; 47:303.</a></li><li><a class="nounderline abstract_t">Wintermeyer P, Baur M, Pilic D, et al. Fructose malabsorption in children with recurrent abdominal pain: positive effects of dietary treatment. Klin Padiatr 2012; 224:17.</a></li><li><a class="nounderline abstract_t">Escobar MA Jr, Lustig D, Pflugeisen BM, et al. Fructose intolerance/malabsorption and recurrent abdominal pain in children. J Pediatr Gastroenterol Nutr 2014; 58:498.</a></li><li><a class="nounderline abstract_t">Chumpitazi B, Tsai C, McMeans A, Shulman R. A low FODMAPS diet ameliorates symptoms in children with irritable bowel syndrome: A double blind, randomized crossover trial. Gastroenterology 2014; 146:S144.</a></li><li><a class="nounderline abstract_t">Chumpitazi BP, Cope JL, Hollister EB, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 2015; 42:418.</a></li><li><a class="nounderline abstract_t">Stróżyk A, Horvath A, Szajewska H. FODMAP dietary restrictions in the management of children with functional abdominal pain disorders: A systematic review. Neurogastroenterol Motil 2022; 34:e14345.</a></li><li><a class="nounderline abstract_t">Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet 2018; 31:239.</a></li><li><a class="nounderline abstract_t">Campo JV, Bridge J, Ehmann M, et al. Recurrent abdominal pain, anxiety, and depression in primary care. Pediatrics 2004; 113:817.</a></li><li><a class="nounderline abstract_t">Dorn LD, Campo JC, Thato S, et al. Psychological comorbidity and stress reactivity in children and adolescents with recurrent abdominal pain and anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42:66.</a></li><li><a class="nounderline abstract_t">Dufton LM, Dunn MJ, Compas BE. Anxiety and somatic complaints in children with recurrent abdominal pain and anxiety disorders. J Pediatr Psychol 2009; 34:176.</a></li><li><a class="nounderline abstract_t">Quigley EM. Probiotics in functional gastrointestinal disorders: what are the facts? Curr Opin Pharmacol 2008; 8:704.</a></li><li><a class="nounderline abstract_t">Korterink JJ, Ockeloen L, Benninga MA, et al. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr 2014; 103:365.</a></li><li><a class="nounderline abstract_t">Wallace C, Gordon M, Sinopoulou V, Akobeng AK. Probiotics for management of functional abdominal pain disorders in children. Cochrane Database Syst Rev 2023; 2:CD012849.</a></li><li><a class="nounderline abstract_t">Ding FCL, Karkhaneh M, Zorzela L, et al. Probiotics for paediatric functional abdominal pain disorders: A rapid review. Paediatr Child Health 2019; 24:383.</a></li><li><a class="nounderline abstract_t">Trivić I, Niseteo T, Jadrešin O, Hojsak I. Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis. Eur J Pediatr 2021; 180:339.</a></li><li><a class="nounderline abstract_t">Horvath A, Dziechciarz P, Szajewska H. Systematic review of randomized controlled trials: fiber supplements for abdominal pain-related functional gastrointestinal disorders in childhood. Ann Nutr Metab 2012; 61:95.</a></li><li><a class="nounderline abstract_t">de Bruijn CM, Rexwinkel R, Gordon M, et al. Dietary interventions for functional abdominal pain disorders in children: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2022; 16:359.</a></li><li><a class="nounderline abstract_t">Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; :CD003460.</a></li><li><a class="nounderline abstract_t">Anheyer D, Frawley J, Koch AK, et al. Herbal Medicines for Gastrointestinal Disorders in Children and Adolescents: A Systematic Review. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Asgarshirazi M, Shariat M, Dalili H. Comparison of the Effects of pH-Dependent Peppermint Oil and Synbiotic Lactol (Bacillus coagulans + Fructooligosaccharides) on Childhood Functional Abdominal Pain: A Randomized Placebo-Controlled Study. Iran Red Crescent Med J 2015; 17:e23844.</a></li><li><a class="nounderline abstract_t">Rexwinkel R, de Bruijn CMA, Gordon M, et al. Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001; 138:125.</a></li><li><a class="nounderline abstract_t">Charrois TL, Hrudey J, Gardiner P, et al. Peppermint oil. Pediatr Rev 2006; 27:e49.</a></li><li><a class="nounderline abstract_t">Kligler B, Chaudhary S. Peppermint oil. Am Fam Physician 2007; 75:1027.</a></li><li><a class="nounderline abstract_t">Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337:a2313.</a></li><li><a class="nounderline abstract_t">Brusaferro A, Farinelli E, Zenzeri L, et al. The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence. Paediatr Drugs 2018; 20:235.</a></li><li><a class="nounderline abstract_t">Pourmoghaddas Z, Saneian H, Roohafza H, Gholamrezaei A. Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Biomed Res Int 2014; 2014:191026.</a></li><li><a class="nounderline abstract_t">Narang M, Shah D, Akhtar H. Efficacy and Safety of Drotaverine Hydrochloride in Children with Recurrent Abdominal Pain: A Randomized Placebo Controlled Trial. Indian Pediatr 2015; 52:847.</a></li><li><a class="nounderline abstract_t">Karabulut GS, Beşer OF, Erginöz E, et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil 2013; 19:90.</a></li><li><a class="nounderline abstract_t">de Bruijn CMA, Rexwinkel R, Gordon M, et al. Antidepressants for functional abdominal pain disorders in children and adolescents. Cochrane Database Syst Rev 2021; 2:CD008013.</a></li><li><a class="nounderline abstract_t">Madani S, Cortes O, Thomas R. Cyproheptadine Use in Children With Functional Gastrointestinal Disorders. J Pediatr Gastroenterol Nutr 2016; 62:409.</a></li><li><a class="nounderline abstract_t">Rodriguez L, Diaz J, Nurko S. Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children. J Pediatr 2013; 163:261.</a></li><li><a class="nounderline abstract_t">Sadeghian M, Farahmand F, Fallahi GH, Abbasi A. Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial. Minerva Pediatr 2008; 60:1367.</a></li><li><a class="nounderline abstract_t">Krasaelap A, Sood MR, Li BUK, et al. Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol 2020; 18:1987.</a></li><li><a class="nounderline abstract_t">Kovacic K, Hainsworth K, Sood M, et al. Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. Lancet Gastroenterol Hepatol 2017; 2:727.</a></li><li><a class="nounderline abstract_t">Santucci NR, King C, El-Chammas KI, et al. Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents with functional abdominal pain disorders. Neurogastroenterol Motil 2022; 34:e14358.</a></li><li><a class="nounderline abstract_t">van Tilburg MAL. Can we treat visceral hypersensitivity in functional abdominal pain? Lancet Gastroenterol Hepatol 2017; 2:694.</a></li><li class="breakAll">US Food and Drug Administration. FDA permits marketing of first medical device for relief of pain associated with irritable bowel syndrome in patients 11-18 years of age. 2019. Available at: www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-relief-pain-associated-irritable-bowel-syndrome-patients (Accessed on January 22, 2020).</li><li><a class="nounderline abstract_t">See MC, Birnbaum AH, Schechter CB, et al. Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. Dig Dis Sci 2001; 46:985.</a></li><li class="breakAll">US Food and Drug Administration. FDA news release. FDA requests removal of all ranitidine products (zantac) from the market. Available at: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market (Accessed on April 01, 2020).</li><li class="breakAll">Australian Government. Department of Health. Therapeutic Goods Administration. Ranitidine. Update 2 -- contamination with N-nitrosodimethylamine. Available at: https://www.tga.gov.au/alert/ranitidine-0 (Accessed on April 04, 2020).</li><li><a class="nounderline abstract_t">Gray L. Chronic abdominal pain in children. Aust Fam Physician 2008; 37:398.</a></li><li><a class="nounderline abstract_t">Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017; 3:CD011194.</a></li><li><a class="nounderline abstract_t">Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev 2018; 10:CD009431.</a></li><li><a class="nounderline abstract_t">Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5:e15591.</a></li><li><a class="nounderline abstract_t">Lembo A, Kelley JM, Nee J, et al. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. Pain 2021; 162:2428.</a></li><li><a class="nounderline abstract_t">Nurko S, Saps M, Kossowsky J, et al. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial. JAMA Pediatr 2022; 176:349.</a></li><li><a class="nounderline abstract_t">Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2011; 52:382.</a></li><li><a class="nounderline abstract_t">Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17:1314.</a></li><li><a class="nounderline abstract_t">Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163:65.</a></li><li><a class="nounderline abstract_t">Giannetti E, Maglione M, Sciorio E, et al. Do Children Just Grow Out of Irritable Bowel Syndrome? J Pediatr 2017; 183:122.</a></li><li class="breakAll">Apley J. The Child with Abdominal Pains, 2nd ed, Blackwell Scientific Publications, Oxford 1975.</li><li><a class="nounderline abstract_t">Walker LS, Guite JW, Duke M, et al. Recurrent abdominal pain: a potential precursor of irritable bowel syndrome in adolescents and young adults. J Pediatr 1998; 132:1010.</a></li><li><a class="nounderline abstract_t">Howell S, Poulton R, Talley NJ. The natural history of childhood abdominal pain and its association with adult irritable bowel syndrome: birth-cohort study. Am J Gastroenterol 2005; 100:2071.</a></li><li><a class="nounderline abstract_t">Horst S, Shelby G, Anderson J, et al. Predicting persistence of functional abdominal pain from childhood into young adulthood. Clin Gastroenterol Hepatol 2014; 12:2026.</a></li><li><a class="nounderline abstract_t">Campo JV, Di Lorenzo C, Chiappetta L, et al. Adult outcomes of pediatric recurrent abdominal pain: do they just grow out of it? Pediatrics 2001; 108:E1.</a></li><li><a class="nounderline abstract_t">Hotopf M, Carr S, Mayou R, et al. Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study. BMJ 1998; 316:1196.</a></li><li><a class="nounderline abstract_t">Walker LS, Garber J, Van Slyke DA, Greene JW. Long-term health outcomes in patients with recurrent abdominal pain. J Pediatr Psychol 1995; 20:233.</a></li></ol></div><div id="topicVersionRevision">Topic 112 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11195732" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Biopsychosocial issues in functional abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743510" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Visceral hyperalgesia in children with functional abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997373" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pressure pain threshold in children with recurrent abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17188617" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697134" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impaired accommodation of the proximal stomach in children with recurrent abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8518526" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The pressure pain threshold (PPT) of certain muscles in children suffering from recurrent abdominal pain of non-organic origin. An algometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144632" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Functional Disorders: Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741394" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118316" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic recurrent abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18781121" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chronic abdominal pain in children: what to do following the medical evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144019" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chronic abdominal pain in children: help in spotting the organic diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476299" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Functional abdominal separation anxiety: helping the child return to school.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008416" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical utility of Rome criteria managing functional gastrointestinal disorders in pediatric primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460383" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34793406" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Internet-delivered cognitive behavioral therapy for youth with functional abdominal pain: a randomized clinical trial testing differential efficacy by patient subgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16721324" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Trajectories of symptoms and impairment for pediatric patients with functional abdominal pain: a 5-year longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728528" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognosis of chronic or recurrent abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28262913" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacological interventions for recurrent abdominal pain in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28081889" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Placebo Response in Pediatric Abdominal Pain-Related Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286150" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrent abdominal pain: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21731470" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Functional abdominal pain and irritable bowel syndrome in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476300" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment approaches to irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654611" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Importance of parental conceptual model of illness in severe recurrent abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34560729" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multidisciplinary Care for Refractory Pediatric Functional Abdominal Pain Decreases Emergency and Inpatient Utilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30055266" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multidisciplinary Treatment Reduces Pain and Increases Function in Children With Functional Gastrointestinal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30055266" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multidisciplinary Treatment Reduces Pain and Increases Function in Children With Functional Gastrointestinal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20922066" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Integrative treatment approaches: family satisfaction with a multidisciplinary paediatric Abdominal Pain Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625141" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Factors influencing functional abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625141" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Factors influencing functional abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435708" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Complementary, holistic, and integrative medicine: recurrent abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118972" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Functional abdominal pain syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31575623" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Unintentional Symptom Intensification by Doctors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24951847" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Redux: do little bellyachers grow up to become big bellyachers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26837501" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fifteen-minute consultation: Medically unexplained symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940244" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Functional abdominal pain in childhood and long-term vulnerability to anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30835245" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The Link Between School Attendance and Good Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23412539" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Importance of addressing anxiety in youth with functional abdominal pain: suggested guidelines for physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23277304" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Twelve-month follow-up of cognitive behavioral therapy for children with functional abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781991" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An approach to functional abdominal pain in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495006" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Parent attention versus distraction: impact on symptom complaints by children with and without chronic functional abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11271757" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Coping with stress during childhood and adolescence: problems, progress, and potential in theory and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30270423" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Psychological therapies for the management of chronic and recurrent pain in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28072460" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Psychosocial interventions for recurrent abdominal pain in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35404394" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Psychosocial Interventions for the Treatment of Functional Abdominal Pain Disorders in Children: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919634" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822590" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Audio-recorded guided imagery treatment reduces functional abdominal pain in children: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23220208" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201068" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2708618" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15944167" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15813156" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pain management in children: developmental considerations and mind-body therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21871242" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effects of psychological treatment on recurrent abdominal pain in children - a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269627" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of functional abdominal pain in childhood with cognitive behavioral strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910118" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955885" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Psychological/cognitive behavioral treatment of childhood functional abdominal pain and irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955885" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Psychological/cognitive behavioral treatment of childhood functional abdominal pain and irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28346581" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17090333" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evaluation of guided imagery as treatment for recurrent abdominal pain in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23568514" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310221" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term follow-up of gut-directed hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35759537" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-Term Follow-up of Individual Therapist Delivered and Standardized Hypnotherapy Recordings in Pediatric Irritable Bowel Syndrome or Functional Abdominal Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30502501" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical and Cost Effectiveness of Online Cognitive Behavioral Therapy in Children With Functional Abdominal Pain Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9444896" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28810423" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Psychological factors addressed in cognitive behaviour therapy for paediatric functional abdominal pain: Which are most important to target?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050045" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Yoga Therapy for Abdominal Pain-Related Functional Gastrointestinal Disorders in Children: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641514" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A pilot study of yoga treatment in children with functional abdominal pain and irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149454" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomized trial of yoga for adolescents with irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25025601" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Iyengar yoga for adolescents and young adults with irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529293" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dance and yoga reduced functional abdominal pain in young girls: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698023" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Diet and functional abdominal pain in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28334433" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dietary interventions for recurrent abdominal pain in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110300" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Irritable bowel syndrome and diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24360501" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Child and parent perceived food-induced gastrointestinal symptoms and quality of life in children with functional gastrointestinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337028" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Update on Dietary Management of Childhood Functional Abdominal Pain Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741363" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chronic abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7195004" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Recurrent abdominal pain and lactose absorption in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6407644" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Dietary lactose and the child with abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12800728" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Abdominal pain associated with lactose ingestion in children with lactose intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27355647" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Dietary Carbohydrates and Childhood Functional Abdominal Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244249" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Food-related gastrointestinal symptoms in the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252792" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical, serologic, and histologic features of gluten sensitivity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7714688" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Characterization of symptoms in children with recurrent abdominal pain: resemblance to irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27322560" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Celiac Disease and Wheat Intolerance Syndrome: A Critical Update and Reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29380821" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Randomized Double-Blind Placebo-Controlled Crossover Trial for the Diagnosis of Non-Celiac Gluten Sensitivity in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22825366" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224837" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667239" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728526" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Fructose intolerance in children presenting with abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21913161" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fructose malabsorption in children with recurrent abdominal pain: positive effects of dietary treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24667867" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fructose intolerance/malabsorption and recurrent abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A low FODMAPS diet ameliorates symptoms in children with irritable bowel syndrome: A double blind, randomized crossover trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104013" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35231146" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : FODMAP dietary restrictions in the management of children with functional abdominal pain disorders: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336079" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15060233" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Recurrent abdominal pain, anxiety, and depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12500078" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Psychological comorbidity and stress reactivity in children and adolescents with recurrent abdominal pain and anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577541" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Anxiety and somatic complaints in children with recurrent abdominal pain and anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775516" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Probiotics in functional gastrointestinal disorders: what are the facts?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24236577" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36799531" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Probiotics for management of functional abdominal pain disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31528110" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Probiotics for paediatric functional abdominal pain disorders: A rapid review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32940743" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22889919" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Systematic review of randomized controlled trials: fiber supplements for abdominal pain-related functional gastrointestinal disorders in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35311425" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Dietary interventions for functional abdominal pain disorders in children: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21833945" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562281" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Herbal Medicines for Gastrointestinal Disorders in Children and Adolescents: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26023339" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Comparison of the Effects of pH-Dependent Peppermint Oil and Synbiotic Lactol (Bacillus coagulans + Fructooligosaccharides) on Childhood Functional Abdominal Pain: A Randomized Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34045320" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148527" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815990" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Peppermint oil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17427617" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Peppermint oil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19008265" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29497992" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25089264" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26499007" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Efficacy and Safety of Drotaverine Hydrochloride in Children with Recurrent Abdominal Pain: A Randomized Placebo Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350053" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33560523" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Antidepressants for functional abdominal pain disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26308312" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cyproheptadine Use in Children With Functional Gastrointestinal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419589" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971897" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31622740" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826627" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35293081" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents with functional abdominal pain disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826626" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Can we treat visceral hypersensitivity in functional abdominal pain?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826626" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Can we treat visceral hypersensitivity in functional abdominal pain?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11341669" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11341669" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11341669" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18523690" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Chronic abdominal pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28271513" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Proton pump inhibitors for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30335201" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Prokinetics for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21203519" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Placebos without deception: a randomized controlled trial in irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33605656" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35099543" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21240023" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740443" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263639" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108106" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Do Children Just Grow Out of Irritable Bowel Syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108106" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Do Children Just Grow Out of Irritable Bowel Syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9627595" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Recurrent abdominal pain: a potential precursor of irritable bowel syndrome in adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16128954" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The natural history of childhood abdominal pain and its association with adult irritable bowel syndrome: birth-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24732284" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Predicting persistence of functional abdominal pain from childhood into young adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11433080" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Adult outcomes of pediatric recurrent abdominal pain: do they just grow out of it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552994" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760222" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Long-term health outcomes in patients with recurrent abdominal pain.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
